Kamada (KMDA) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.039x

Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA10.42 Million ≈ $27.92K USD) by net assets (ILA265.23 Million ≈ $711.08K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Kamada for the company's overall valuation and market capitalisation.

Kamada - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Kamada Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kamada ranked by their cash flow conversion efficiency. Explore KMDA cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Hangzhou Juheshun New Material Co Ltd
SHG:605166
-0.008x
Buana Listya Tama Tbk PT
JK:BULL
0.026x
First Carolina Financial Services, Inc.
NYSE:FCBM
0.031x
San Fang Chemical Industry Co Ltd
TW:1307
-0.020x
Equinox India Developments Ltd
NSE:IBREALEST
0.001x
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
0.006x
Zhejiang Baida Precision Mnfg
SHG:603331
0.085x
China Datang Corporation Renewable Power Co. Limited
STU:DT7
0.046x

Annual Cash Flow Conversion Efficiency for Kamada (2007–2024)

The table below shows the annual cash flow conversion efficiency of Kamada from 2007 to 2024. View Kamada (KMDA) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ILA259.46 Million
≈ $695.61K
ILA47.59 Million
≈ $127.60K
0.183x +937.34%
2023-12-31 ILA244.02 Million
≈ $654.21K
ILA4.32 Million
≈ $11.57K
0.018x -89.11%
2022-12-31 ILA176.02 Million
≈ $471.90K
ILA28.59 Million
≈ $76.64K
0.162x +425.62%
2021-12-31 ILA176.82 Million
≈ $474.06K
ILA-8.82 Million
≈ $-23.64K
-0.050x -146.63%
2020-12-31 ILA178.64 Million
≈ $478.92K
ILA19.11 Million
≈ $51.22K
0.107x -47.51%
2019-12-31 ILA135.32 Million
≈ $362.79K
ILA27.57 Million
≈ $73.92K
0.204x +117.11%
2018-12-31 ILA112.38 Million
≈ $301.28K
ILA10.55 Million
≈ $28.27K
0.094x +115.90%
2017-12-31 ILA89.49 Million
≈ $239.92K
ILA3.89 Million
≈ $10.43K
0.043x +52.93%
2016-12-31 ILA66.74 Million
≈ $178.94K
ILA1.90 Million
≈ $5.09K
0.028x +114.74%
2015-12-31 ILA72.51 Million
≈ $194.39K
ILA-13.98 Million
≈ $-37.48K
-0.193x -57.44%
2014-12-31 ILA80.99 Million
≈ $217.14K
ILA-9.92 Million
≈ $-26.59K
-0.122x -185.86%
2013-12-31 ILA89.97 Million
≈ $241.21K
ILA-3.85 Million
≈ $-10.33K
-0.043x +85.28%
2012-12-31 ILA28.39 Million
≈ $76.12K
ILA-8.26 Million
≈ $-22.15K
-0.291x -801.65%
2011-12-31 ILA22.67 Million
≈ $60.79K
ILA940.36K
≈ $2.52K
0.041x -89.67%
2010-12-31 ILA26.49 Million
≈ $71.01K
ILA10.63 Million
≈ $28.50K
0.401x +192.43%
2009-12-31 ILA30.15 Million
≈ $80.83K
ILA-13.09 Million
≈ $-35.10K
-0.434x +56.84%
2008-12-31 ILA12.64 Million
≈ $33.89K
ILA-12.72 Million
≈ $-34.11K
-1.006x -456.76%
2007-12-31 ILA69.57 Million
≈ $186.51K
ILA-12.57 Million
≈ $-33.71K
-0.181x --

About Kamada

TA:KMDA Israel Drug Manufacturers - Specialty & Generic
Market Cap
$377.48 Million
ILA140.80 Billion ILA
Market Cap Rank
#13759 Global
#150 in Israel
Share Price
ILA2441.00
Change (1 day)
-2.55%
52-Week Range
ILA2063.00 - ILA2870.00
All Time High
ILA3940.00
About

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more